Insider Buying: GSK (LON:GSK) Insider Buys 526 Shares of Stock

Key Points

• Wendy Becker, an insider at GSK, purchased 526 shares of the company's stock at an average price of GBX 1,503, totaling approximately £7,905.78.
• GSK's stock recently traded at GBX 1,511, with analysts providing target prices ranging from GBX 1,400 to GBX 2,100 as part of varied ratings from "buy" to "hold."
• The company reported earnings of GBX 75.30 per share for its most recent quarter, with a net margin of 8.02% and a return on equity of 18.08%.

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker acquired 526 shares of the business's stock in a transaction dated Friday, September 19th. The shares were bought at an average price of GBX 1,503 per share, for a total transaction of £7,905.78.

GSK Stock Up 1.0%

Shares of GSK traded up GBX 14.50 during mid-day trading on Monday, hitting GBX 1,511. 3,149,587 shares of the company traded hands, compared to its average volume of 12,160,349. GSK plc has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,560.50. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The company has a market capitalization of £60.86 billion, a PE ratio of 1,827.09, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The business has a 50 day moving average of GBX 1,436.63 and a 200 day moving average of GBX 1,431.78.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. cut their price objective on shares of GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a report on Monday, August 4th. Berenberg Bank reiterated a "hold" rating and issued a GBX 1,600 price target on shares of GSK in a report on Friday, July 18th. Shore Capital reiterated a "buy" rating and issued a GBX 2,100 price target on shares of GSK in a report on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 1,450 price target on shares of GSK in a report on Thursday, July 31st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.